Technology evaluation: PK1, Pfizer/Cancer Research UK.
Pfizer (formerly Pharmacia) is collaborating with Cancer Research UK in developing PK1 (FCE-28068) for the potential treatment of various cancers. PK1 is an N-(2-hydroxypropyl) methacrylamide (HPMA) co-polymer-doxorubicin conjugate, attached by a peptide linker, which is currently undergoing phase II trials for breast, non-small-cell lung and colon cancers.